Search

Check out this episode of the Phage Therapy Today podcast, which features Dr. Mercedes Gonzalez from INCATE (an AMR startup funder/accelerator) and Dr. Gregorio Iraola at Kinzbio, an INCATE recipient and founder of a new phage startup in Ur

The CDC has launched an Antimicrobial Resistance Investment Map (interestingly, they are calling it ‘AR’ now — is this our new acronym for AMR?). The map illustrates the allocation of CDC funds in the US and abroad. Explore funding landscap

CARB-X has announced its 2019 calls for proposals. Funding Round 1 covers non-traditional alternatives to antibiotics, including phage! Learn how to apply by tuning in May 16 for a webinar. Expressions of interest can be submitted June 3 –

CARB-X has announced its 2019 calls for proposals. Funding Round 1 covers non-traditional alternatives to antibiotics, including phage! Learn how to apply by tuning in May 16 for a webinar. Expressions of interest can be submitted June 3 –

If you want to better understand the funds available for AMR drug development, here's a slideshow from a talk given this week by John Rex of the Wellcome Trust. It explains what's available, the different funding models that exist, provides

If you want to better understand the funds available for AMR drug development, here's a slideshow from a talk given this week by John Rex of the Wellcome Trust. It explains what's available, the different funding models that exist, provides

CARB-X’s next Expression of Interest window is scheduled for November 10, 2026 at 10:00 ET through November 23 at 23:59 ET. The 2026 funding round lists four themes: Gram-negative therapeutics, novel target-based chemistry, non-vaccine neon

EMBO accepts postdoctoral fellowship applications throughout the year, with the next cutoff on January 22, 2027 at 14:00 CET. The fellowships support life-science research and require international mobility. EMBO

HERA Invest offers non-dilutive venture loans covering up to 50% of investment costs for innovative SMEs developing medical countermeasures, including AMR technologies. Applications are accepted on a rolling basis. Applicants must already h

The University of Exeter lists a PhD project on optimising phage treatments for bacterial co-infections in the GW4 BioMed3 MRC doctoral programme for 2027/28 entry. Applications are due at 5 pm on October 21, 2026, but may close early. Fund

The Novo Nordisk Foundation’s Challenge Programme 2027 supports early-stage proof-of-concept research on rapid, minimally invasive and affordable point-of-care tests for lower respiratory tract infections. Grants of DKK 30–75 million run fo